Extrait

This phase I/II, multi-center study is designed to determine the pharmacokinetic profile of Raltegravir in patients with end stage liver disease and to assess drug-drug interaction when Raltegravir is combined with immunosuppressive therapy in liver transplant recipients.

Critère d'inclusion

• HIV infection ,Liver Failure ,Evidence of Liver Transplantation

Liens

• nct